Apricus Biosciences Company Profile (NASDAQ:APRI)

About Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences logoApricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:APRI
  • CUSIP: N/A
  • Web: www.apricusbio.com
Capitalization:
  • Market Cap: $7.35 million
  • Outstanding Shares: 7,741,000
Average Prices:
  • 50 Day Moving Avg: $1.25
  • 200 Day Moving Avg: $1.85
  • 52 Week Range: $0.26 - $4.07
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 2.57
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.76 million
  • Price / Sales: 1.28
  • Book Value: ($0.97) per share
  • Price / Book: -0.98
Profitability:
  • EBIDTA: ($15,100,000.00)
  • Net Margins: -117.82%
  • Return on Assets: -134.36%
Debt:
  • Current Ratio: 0.57%
  • Quick Ratio: 0.51%
Misc:
  • Average Volume: 433,297 shs.
  • Beta: 0.26
  • Short Ratio: 3.56
 

Frequently Asked Questions for Apricus Biosciences (NASDAQ:APRI)

What is Apricus Biosciences' stock symbol?

Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."

How were Apricus Biosciences' earnings last quarter?

Apricus Biosciences Inc (NASDAQ:APRI) issued its quarterly earnings data on Thursday, May, 11th. The company reported $1.04 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.25 by $0.21. During the same period in the prior year, the company posted ($0.50) earnings per share. View Apricus Biosciences' Earnings History.

Are investors shorting Apricus Biosciences?

Apricus Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 1,182,312 shares, an increase of 76.5% from the April 28th total of 669,780 shares. Based on an average daily volume of 709,886 shares, the days-to-cover ratio is presently 1.7 days. Approximately 10.1% of the company's stock are short sold.

Who are some of Apricus Biosciences' key competitors?

Who owns Apricus Biosciences stock?

Apricus Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Sarissa Capital Management LP (18.70%) and Vanguard Group Inc. (0.00%). View Institutional Ownership Trends for Apricus Biosciences.

Who bought Apricus Biosciences stock? Who is buying Apricus Biosciences stock?

Apricus Biosciences' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Apricus Biosciences.

How do I buy Apricus Biosciences stock?

Shares of Apricus Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Apricus Biosciences stock cost?

One share of Apricus Biosciences stock can currently be purchased for approximately $0.95.

Analyst Ratings

Consensus Ratings for Apricus Biosciences (NASDAQ:APRI) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Apricus Biosciences (NASDAQ:APRI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/26/2017Rodman & RenshawInitiated CoverageBuy -> BuyLowView Rating Details
3/15/2016Taglich BrothersLower Price TargetSpeculative Buy$4.25 -> $2.95N/AView Rating Details
3/11/2016Dawson JamesReiterated RatingBuyN/AView Rating Details
12/9/2015Sterne Agee CRTDowngradeBuy -> NeutralN/AView Rating Details
11/6/2015Roth CapitalDowngradeBuy -> Neutral$1.50N/AView Rating Details
8/13/2015Ascendiant Capital MarketsInitiated CoverageBuy$2.50N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Apricus Biosciences (NASDAQ:APRI)
Earnings by Quarter for Apricus Biosciences (NASDAQ:APRI)
Earnings History by Quarter for Apricus Biosciences (NASDAQ:APRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017$1.25$1.04$12.00 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.15)($0.04)$3.44 million$0.40 millionViewN/AView Earnings Details
11/8/2016Q316($0.60)($0.19)$1.91 million$4.30 millionViewListenView Earnings Details
8/4/2016Q216($0.08)($0.05)$1.78 million$0.46 millionViewListenView Earnings Details
5/9/2016Q116($0.09)($0.09)$0.83 million$0.63 millionViewN/AView Earnings Details
3/9/2016Q415($0.11)($0.05)$1.81 million$2.60 millionViewListenView Earnings Details
11/5/2015Q315($0.11)($0.10)$1.42 million$1.30 millionViewListenView Earnings Details
8/5/2015Q2($0.13)($0.10)$0.70 million$0.46 millionViewListenView Earnings Details
5/11/2015Q1($0.10)($0.13)$0.95 million$0.48 millionViewListenView Earnings Details
3/16/2015Q4($0.12)($0.09)$0.67 million$1.91 millionViewListenView Earnings Details
11/10/2014Q314($0.09)($0.08)$1.23 million$1.90 millionViewN/AView Earnings Details
5/12/2014Q114($0.03)($0.09)$2.83 millionViewN/AView Earnings Details
3/17/2014Q212($0.06)($0.04)$2.00 million$0.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Apricus Biosciences (NASDAQ:APRI)
2017 EPS Consensus Estimate: ($0.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.04)($0.04)($0.04)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171($0.02)($0.02)($0.02)
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Apricus Biosciences (NASDAQ:APRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Apricus Biosciences (NASDAQ:APRI)
Insider Ownership Percentage: 3.21%
Insider Trades by Quarter for Apricus Biosciences (NASDAQ:APRI)
Institutional Ownership by Quarter for Apricus Biosciences (NASDAQ:APRI)
Insider Trades by Quarter for Apricus Biosciences (NASDAQ:APRI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/3/2016Alexander J DennerMajor ShareholderBuy6,647,728$0.88$5,850,000.64View SEC Filing  
1/12/2016Alexander J DennerMajor ShareholderBuy1,306,819$0.88$1,150,000.72View SEC Filing  
12/29/2014Brian DorseyInsiderBuy10,000$1.05$10,500.00View SEC Filing  
12/22/2014Richard W PascoeCEOBuy10,000$1.02$10,200.00View SEC Filing  
10/23/2014Sandford D SmithDirectorBuy26,500$1.57$41,605.00View SEC Filing  
1/3/2014Leonard A OppenheimDirectorSell15,212$2.49$37,877.88View SEC Filing  
12/26/2013Kleanthis G XanthopoulosDirectorSell17,184$2.55$43,819.20View SEC Filing  
6/21/2013Kleanthis G XanthopoulosDirectorSell2,864$2.52$7,217.28View SEC Filing  
5/23/2013Richard W PascoeCEOBuy35,000$2.85$99,750.00View SEC Filing  
5/23/2013Rusty RayDirectorBuy5,000$2.85$14,250.00View SEC Filing  
5/23/2013Steven Robert MartinCFOBuy20,000$2.85$57,000.00View SEC Filing  
5/21/2013Kleanthis G XanthopoulosDirectorSell2,864$3.36$9,623.04View SEC Filing  
8/20/2012Edward M CoxVPBuy1,500$2.73$4,095.00View SEC Filing  
8/17/2012Rusty RayDirectorBuy4,000$2.81$11,240.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Apricus Biosciences (NASDAQ:APRI)
Latest Headlines for Apricus Biosciences (NASDAQ:APRI)
Source:
DateHeadline
americanbankingnews.com logoApricus Biosciences Inc (APRI) Short Interest Update
www.americanbankingnews.com - May 28 at 7:02 AM
prnewswire.com logoTechnical Reports on Drug Makers Stocks -- Synergy Pharma, Novo Nordisk, Apricus Biosciences, and - PR Newswire (press release)
www.prnewswire.com - May 22 at 8:03 AM
globenewswire.com logoApricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 13 at 3:39 PM
reuters.com logoBRIEF-Apricus Biosciences Q1 earnings per share $1.04
www.reuters.com - May 12 at 4:10 PM
finance.yahoo.com logoEdited Transcript of APRI earnings conference call or presentation 11-May-17 8:30pm GMT
finance.yahoo.com - May 12 at 4:10 PM
americanbankingnews.com logoApricus Biosciences Inc (APRI) Releases Earnings Results, Misses Estimates By $0.21 EPS
www.americanbankingnews.com - May 12 at 11:26 AM
nasdaq.com logoApricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - May 12 at 2:04 AM
rttnews.com logoEARNINGS SUMMARY: Details of Apricus Biosciences, Inc. Q1 Earnings Report
www.rttnews.com - May 11 at 9:03 PM
finance.yahoo.com logoApricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 9:03 PM
finance.yahoo.com logoApricus posts 1Q profit
finance.yahoo.com - May 11 at 9:03 PM
finance.yahoo.com logoInvestor Network: APRICUS BIOSCIENCES, INC. to Host Earnings Call
finance.yahoo.com - May 11 at 4:00 PM
americanbankingnews.com logoApricus Biosciences Inc (APRI) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - May 5 at 11:13 PM
americanbankingnews.com logoApricus Biosciences Inc (APRI) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - May 5 at 10:23 PM
globenewswire.com logoApricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements - GlobeNewswire (press release)
globenewswire.com - May 4 at 3:42 PM
finance.yahoo.com logoApricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study - Yahoo Finance
finance.yahoo.com - May 4 at 3:42 PM
nasdaq.com logoApricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call - Nasdaq
www.nasdaq.com - May 4 at 3:42 PM
finance.yahoo.com logoApricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call
finance.yahoo.com - May 4 at 3:42 PM
finance.yahoo.com logoApricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study
finance.yahoo.com - May 4 at 3:42 PM
americanbankingnews.com logoApricus Biosciences (APRI) Receiving Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - May 4 at 9:42 AM
finance.yahoo.com logoApricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements - Yahoo Finance
finance.yahoo.com - May 3 at 3:40 PM
finanznachrichten.de logoApricus Biosciences, Inc.: Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements
www.finanznachrichten.de - May 3 at 9:55 AM
finance.yahoo.com logoApricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements
finance.yahoo.com - May 3 at 9:55 AM
americanbankingnews.com logoApricus Biosciences (APRI) Receives Daily Media Sentiment Score of 0.02
www.americanbankingnews.com - May 1 at 12:36 PM
americanbankingnews.com logoApricus Biosciences (APRI) Getting Somewhat Favorable News Coverage, Study Shows
www.americanbankingnews.com - April 28 at 11:06 AM
americanbankingnews.com logoApricus Biosciences Inc (APRI) Short Interest Down 8.8% in April
www.americanbankingnews.com - April 27 at 12:10 PM
americanbankingnews.com logoApricus Biosciences (APRI) Receiving Somewhat Positive News Coverage, Report Finds
www.americanbankingnews.com - April 25 at 2:52 PM
americanbankingnews.com logoApricus Biosciences (APRI) Earning Somewhat Favorable News Coverage, Report Shows
www.americanbankingnews.com - April 22 at 9:13 AM
benzinga.com logo15 Biggest Mid-Day Losers For Friday | Benzinga - Benzinga
www.benzinga.com - April 21 at 8:37 PM
globenewswire.com logoApricus Biosciences Announces Pricing of $7.0 Million Public Offering - GlobeNewswire (press release)
globenewswire.com - April 21 at 3:36 PM
finance.yahoo.com logoETFs with exposure to Apricus Biosciences, Inc. : April 19, 2017
finance.yahoo.com - April 19 at 3:34 PM
americanbankingnews.com logoApricus Biosciences (APRI) Receives Daily Media Sentiment Rating of 0.16
www.americanbankingnews.com - April 18 at 11:10 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-BofA, Cardinal Health, Harley-Davidson - Nasdaq
www.nasdaq.com - April 18 at 8:48 AM
benzinga.com logo15 Biggest Mid-Day Losers For Monday - Benzinga
www.benzinga.com - April 17 at 3:31 PM
finance.yahoo.com logoApricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials - Yahoo Finance
finance.yahoo.com - April 13 at 3:45 PM
finance.yahoo.com logoETFs with exposure to Apricus Biosciences, Inc. : April 7, 2017
finance.yahoo.com - April 7 at 8:38 PM
prnewswire.com logoDrug Makers Stocks Under Scanner -- Synergy Pharma, Novo ... - PR Newswire (press release)
www.prnewswire.com - April 7 at 6:44 AM
prnewswire.com logoAkcea Therapeutics Announces Three Additions to Board of Directors
www.prnewswire.com - March 28 at 10:13 AM
streetinsider.com logoIonis (IONS) Subsidiary Akcea Therapeutics Announces Three Additions to Board of Directors
www.streetinsider.com - March 28 at 10:13 AM
finance.yahoo.com logoAPRICUS BIOSCIENCES, INC. Financials
finance.yahoo.com - March 17 at 4:13 PM
finanznachrichten.de logoApricus Biosciences, Inc.: Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results
www.finanznachrichten.de - March 14 at 3:31 PM
rttnews.com logoEARNINGS SUMMARY: Details of Apricus Biosciences, Inc. Q4 Earnings Report
www.rttnews.com - March 14 at 3:31 PM
reuters.com logoBRIEF-Apricus Biosciences Q4 loss per share $0.04
www.reuters.com - March 14 at 3:31 PM
biz.yahoo.com logoAPRICUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
us.rd.yahoo.com - March 14 at 3:31 PM
us.rd.yahoo.com logoApricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 14 at 3:31 PM
rttnews.com logoAPRI On Track, Stellar Bio Shines, FDA Nod For NVS, Study Results Heat Up HTBX - RTT News
www.rttnews.com - March 14 at 5:39 AM
biz.yahoo.com logoQ4 2016 Apricus Biosciences Inc Earnings Release - 4:01 pm ET
biz.yahoo.com - March 13 at 8:01 AM
finanznachrichten.de logoApricus Biosciences, Inc.: Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals
www.finanznachrichten.de - March 10 at 9:24 PM
streetinsider.com logoPre-Open Movers 03/09: (APRI) (VVUS) (ELF) Higher; (TLRD) (SPPI) (RATE) Lower (more...)
www.streetinsider.com - March 10 at 2:03 AM
finance.yahoo.com logoApricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call
finance.yahoo.com - March 9 at 3:58 PM
investopedia.com logoApricus Biosciences Sells ED Therapy Rights
www.investopedia.com - March 9 at 3:58 PM

Social

Chart

Apricus Biosciences (APRI) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff